Pentosan Polysulfate Sodium interactions
Checked as Pentosan polysulfate in this data source.
Full monograph for Pentosan Polysulfate SodiumCheck it against another medicine
Medicines
39 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Acalabrutinib | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Allium cepa + Heparin + Allantoin | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Alteplase | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Apixaban | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Aspirin | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Aspirin + Dipyridamole | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants…2 documented mechanisms | 2 sources — open the full entry |
| Betrixaban | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Bivalirudin | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Cabozantinib | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Cilostazol | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Clopidogrel + Aspirin | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants…2 documented mechanisms | 2 sources — open the full entry |
| Clopidogrel Bisulphate | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Dabigatran Etexilate Mesylate | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 1 sources — open the full entry |
| Dalteparin Sodium | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Dasatinib | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Dipyridamole | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Enoxaparin Sodium | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Eplerenone | Moderate | Synergy | Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia. Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists… | 3 sources — open the full entry |
| Eptifibatide | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Finerenone | Moderate | Synergy | Heparin and low molecular weight heparins (LMWHs) may cause hyperkalemia. Concomitant use with potassium-sparing diuretics or aldosterone receptor antagonists… | 3 sources — open the full entry |
| Fondaparinux Sodium | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Furosemide + Spironolactone | Moderate | Synergy | The concomitant use of potassium-sparing diuretics and heparin or low molecular weight heparins may increase the risk of hyperkalemia. Both types of… | 3 sources — open the full entry |
| Heparin Sodium | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Ibrutinib | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Nintedanib | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Ponatinib Hydrochloride | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Prasugrel Hydrochloride | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Ramucirumab | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Regorafenib Monohydrate | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Rivaroxaban | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Ruxolitinib (Oral) | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Spironolactone | Moderate | Synergy | The concomitant use of potassium-sparing diuretics and heparin or low molecular weight heparins may increase the risk of hyperkalemia. Both types of… | 3 sources — open the full entry |
| Streptokinase | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Tenecteplase | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Ticagrelor | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Tirofiban Hydrochloride | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Trastuzumab Emtansine | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
| Triamterene + Hydrochlorothiazide | Moderate | Synergy | The concomitant use of potassium-sparing diuretics and heparin or low molecular weight heparins may increase the risk of hyperkalemia. Both types of… | 3 sources — open the full entry |
| Warfarin Sodium | Moderate | Synergy | Theoretically, pentosan polysulfate sodium may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants… | 2 sources — open the full entry |
Conditions
Conditions in which Pentosan Polysulfate Sodium needs care, as documented in this source.
Hemorrhage
ModeratePentosan polysulfate sodium induces weak anticoagulant activity (1/15 the activity of heparin). Bleeding complications (ecchymosis, epistaxis, bleeding gums) have occurred. Increases in PT and PTT, as well as thrombocytopenia, have been reported rarely. Therapy with pentosan polysulfate sodium should be administered cautiously in patients with coagulation disorders, bleeding, or other conditions that may increase the risk for bleeding.
3 sources
- "Product Information. Elmiron (pentosan polysulfate sodium)." Baker Norton Pharmaceuticals (2001):
- Goad KE, Horne MK 3rd, Gralnick HR "Pentosan-induced thrombocytopenia: support for an immune complex mechanism." Br J Haematol 88 (1994): 803-8
- Tardy-Poncet B, Tardy B, Grelac F, Reynaud J, Mismetti P, Bertrand JC, Guyotat D "Pentosan polysulfate-induced thrombocytopenia and thrombosis." Am J Hematol 45 (1994): 252-7
Hepatic Insufficiency
ModerateThe use of pentosan polysulfate sodium has not been studied in patients with hepatic insufficiency. Because there is evidence of hepatic contribution to the elimination of this drug, hepatic impairment may have an impact on its pharmacokinetics. Caution should be exercised when using pentosan polysulfate sodium in this patient population.
3 sources
- "Product Information. Elmiron (pentosan polysulfate sodium)." Baker Norton Pharmaceuticals (2001):
- Peters M, Witvrouw M, De Clercq E, Ruf B "Pharmacokinetics of intravenous pentosan polysulphate (HOE/BAY 946) in HIV-positive patients." AIDS 5 (1991): 1534-5
- MacGregor IR, Dawes J, Paton L, Pepper DS, Prowse CV, Smith M "Metabolism of sodium pentosan polysulphate in man--catabolism of iodinated derivatives." Thromb Haemost 51 (1984): 321-5